The Regulatory Catalyst: Defining the "Medical-Grade" Lane

On January 6, 2026, the FDA released its revised "General Wellness Policy for Low-Risk Devices," a document Commissioner Marty Makary framed as the agency "getting out of the way" of consumer innovation.  The policy allows wearables and apps that estimate physiological parameters — such as blood pressure, glucose trends, and heart rate variability — to operate without premarket review, provided they avoid specific disease-related claims.

However, the guidance introduces a critical "Validation Tension."  While wellness products are now permitted to display values that "mimic those used clinically," the FDA explicitly prohibits them from claiming "clinical accuracy," "clinical equivalence," or "medical-grade" status unless they undergo formal regulatory scrutiny.  For the digital health industry, this creates a bifurcated market: a low-margin consumer wellness tier and a high-margin, regulated clinical tier.

The Evidence Gap: The Limits of Descriptive Data

This regulatory boundary creates a significant "Measurement-to-Management Gap."  Most consumer health tools are limited to "descriptive" outputs — tracking patterns or trends without providing a clinical conclusion.  As soon as a device prompts a specific clinical action or references a diagnostic threshold (e.g., "abnormal" vs. "normal"), it is reclassified as a medical device subject to full FDA oversight.

For companies seeking to enter the lucrative clinical market—where their technology is used by physicians to manage chronic disease or titrate medication — the lack of Verified Clinical Veracity is a terminal barrier.  "Data Exhaust" from unvalidated sensors is insufficient to support the medical-grade claims required for physician trust, payer reimbursement, and premium pricing.

The Circle Solution: The Infrastructure of Clinical Validation

The Circles platform provides the bridge for digital health companies to move from "wellness" to "medical-grade" status through Outcome Engineering.  By embedding Regulatory-Grade Governance into the data collection process, Circles provide the evidence necessary to satisfy the FDA’s highest standards.

Verified Clinical Veracity:  Circles capture the "Human Ground Truth" required to validate sensor-based outputs against gold-standard clinical benchmarks.  This allows developers to move beyond "descriptive trends" to "evaluative insights" backed by an audit-ready dataset.

Human-in-the-Loop Governance:  The new guidance emphasizes that Clinical Decision Support (CDS) tools must allow healthcare professionals to "independently review" the basis for recommendations.  Circles’ architecture is designed for this transparency, ensuring that the clinician remains the primary decision-maker while the data remains Audit-Ready.

Insurable Integrity:  For a digital health asset to be "prescribable," it must possess Insurable Integrity.  Circles provide the longitudinal tracking of outcomes that proves to payers and providers that a technology is a reliable medical instrument rather than a consumer curiosity.

Strategic Outcome: Reclassifying Digital Health Assets

The 2026 guidance has fundamentally changed the valuation logic for health technology.  A wellness tool that remains in the "low-risk" category is valued as a consumer subscription business, subject to high churn and price sensitivity.

By utilizing Circles to provide Verified Clinical Veracity, an organization can reclassify its technology as a Tech-Enabled Asset.  This transition from "Wellness" to "Medical-Grade" is a primary driver of Multiple Expansion, moving an entity from a consumer-tech multiple to a 12–15x clinical-asset multiple.  In the new regulatory era, the value of the platform is defined by the Insurable Integrity of its data, not just the features of its hardware.

‍Get involved or learn more — contact us today!

If you are interested in contributing to this important initiative or learning more about how you can be involved, please contact us.